DOC — Claude Opus 4.8

Let me pull the year-ago Q2 2025 figures for comparison context.# Healthpeak Properties (DOC) — Q2 2026 Earnings Preview

Report expected Wednesday, August 4, 2026 (Q2 2026 Earnings Call)

1. The Setup: A Company Transformed by the Janus Living IPO

DOC (Healthpeak Properties, the diversified healthcare REIT that trades under the ticker inherited from the Physicians Realty merger) walks into this print riding real momentum. The stock closed at $21.65 on Aug 3, up roughly 34% year-to-date from ~$16.20 in early January — a dramatic re-rating for a name that spent most of 2024–2025 stuck in the mid-teens.

The single most important development this year was the March 2026 IPO of Janus Living (NYSE: JAN), Healthpeak's senior housing business. This is now the lens through which the Q2 story must be read:

The IPO priced at the high end, generating ~$880M of net proceeds in an oversubscribed, upsized deal.
Healthpeak retained an ~81.6% stake; by early May that stake was worth ~$5.7B, and JAN has since rallied from ~$23.6 (IPO) to ~$29.6, adding meaningful mark-to-market value to Healthpeak's holding.
Crucially, management timed $714M of senior housing acquisitions onto Healthpeak's own balance sheet before the IPO, then contributed them to Janus — capturing a valuation arbitrage (senior housing FFO now valued ~20 turns higher than Healthpeak's own multiple) while keeping DOC's senior housing exposure essentially unchanged.

What to listen for: Because Janus is consolidated into Healthpeak's financials (with an ~18.4% minority interest deduction), the Q2 numbers will again carry Janus's revenue growth, its public-company costs, and the temporary drag from undeployed IPO cash. Management framed the IPO as earnings-neutral to DOC in 2026 and accretive in 2027+ (~$0.04 run-rate accretion once the cash is deployed). Watch for: (a) progress deploying the ~$750M of cash into acquisitions, and (b) an update on the ~$400M of senior housing acquisitions JAN was under contract on at Q1.

2. Earnings & Guidance — What the Numbers Should Look Like

Metric	Q2 2025 (actual)	Q1 2026 (actual)	FY2026 Guidance
FFO as Adjusted / sh	$0.46	$0.45	$1.71 – $1.75
Nareit FFO / sh	—	$0.42	$1.68 – $1.72
Diluted EPS	—	$0.28	$0.46 – $0.50
Total SS Cash NOI growth	+3.5%	0.0%	(1.0%) – 1.0%
Net Debt / Adj. EBITDA	5.2x	5.4x	—

Key modeling nuance: Management explicitly guided that Q1's $0.45 was elevated by the on-balance-sheet acquisitions held ahead of the IPO, and that quarterly run-rate should settle around ~$0.43 (±$0.01) off the guidance midpoint. So a Q2 print in the $0.42–$0.43 zone is roughly "in line," not a miss versus the strong Q1.

Two known H2 headwinds management flagged that should start showing up now: - ~$650M of 3.5% senior notes were refinanced in June at today's much higher rates — an interest-expense step-up in the back half. - Full-year interest expense guided ~$20M higher and G&A ~$5M higher, partly offset by senior housing outperformance and deployment of proceeds.

Guidance-raise watch: DOC nudged FFO guidance up $0.01 at Q1 on the back of accretive buybacks. With the stock now much higher (making new leverage-neutral buybacks less compelling) but recap/disposition proceeds and JAN accretion flowing in, a modest raise is plausible but not a given. A raise to same-store NOI guidance is possible — management deferred updating segment same-store at Q1 and said they'd "reevaluate over the course of the year."

3. Segment Watch List

Lab / Life Science — the swing factor and the bull case

This is where the debate lives. After a brutal 2025 (Q2 '25 saw total occupancy fall ~150 bps on failed-capital-raise tenant departures), management turned notably more upbeat at Q1 2026: - Total lab occupancy rose sequentially to 77.7% (from 77% at YE2025), with a stated goal of +100 bps by year-end 2026. - The setup rests on ~400K sq ft of 2026 expirations offset by >500K sq ft of commencements — i.e., embedded net absorption. Watch whether SNO (signed-not-occupied) leases are actually commencing on schedule. - Management cited the strongest biotech equity-issuance month (April) since early 2021 and a broad-based ~2M sq ft pipeline. The Gateway (South SF) acquisition is reportedly leasing ahead of underwriting. - Key forward tell: Brinker hinted the 2027 lab renewal rate could jump to ~50%+ (vs. weak 2026). Any hardening of that view is a positive catalyst. - Cash re-leasing spreads have been positive but modest (+3.5% in Q1); watch face rents (~$60/sf NNN) given a larger peer is guiding to ugly spreads.

Outpatient Medical — the steady compounder

Consistently the strongest, most predictable engine: - Q1 2026: +2.4% same-store, ~91% occupancy, +5.4% cash re-leasing spreads, 79% retention, 3% escalators, and unusually low leasing costs (~10% of annual rent, much of it done in-house). - Watch for continued strong renewal volume (Q1 had post-quarter momentum of ~1M sq ft executed + LOIs) and any commentary on the proposed CMS "inpatient-only list" changes, which management views as a structural demand tailwind for higher-acuity outpatient centers.

Senior Housing (via Janus) — the growth story

Q1 senior housing same-store was +13.8% and Janus posted 35% revenue / 42% EBITDA growth with record entry-fee volumes. Detailed color will again come on the separate Janus earnings call, but DOC's earnings now inherit the segment's strength.

4. Capital Allocation — a lot in motion

Capital recycling: targeting ~$1B of recaps/dispositions and ~$1B of acquisitions in 2026. As of early May, ~$270M of proceeds were in, and management flagged $700M+ of additional transactions "underway" at cap rates ~200 bps inside what the stock implies. Progress here is a key credibility check.
Blackstone JV: the March recap (80% of a 6-property MOB portfolio at a 6.1% cash cap rate, $170M proceeds, ~$508/sf) established a template. Watch for expansion — management signaled future recaps/acquisitions with Blackstone at 10–20% co-invest stakes.
Buybacks: ~$100M repurchased in April at $16.81 (>10% FFO yield); ~$306M remained under the $500M authorization at Q1. With shares now ~$21.65, the math on new buybacks is far less accretive — expect a more selective tone.
Balance sheet: 5.4x net debt/EBITDA, plus a $400M undrawn delayed-draw term loan (SOFR+80, matures 2031) providing dry powder through December 2026.

5. Valuation & Sentiment

At $21.65, DOC trades at roughly 12.5x the FY2026 FFO-as-Adjusted midpoint (~$1.73) — a re-rating from the ~9–10x range earlier in the year, largely driven by the Janus value-crystallization thesis.
The $1.22 annualized dividend now yields ~5.6% (down from the "7.5%" management touted at Q1 when the stock was ~$16).
The stock has quietly ground higher into the print (from ~$19.5 in early May to ~$22 in late July), so expectations have risen — the bar for a positive reaction is higher than it was three months ago. Note shares slipped from ~$22.8 (Jul 28) to $21.65 (Aug 3) heading in.

6. Key Risks / Things That Could Go Wrong

Lab occupancy stalls. If the +100 bps year-end target starts looking shaky (delayed commencements, new tenant credit failures), the entire "pendulum is swinging" narrative takes a hit.
Sentiment/valuation risk. After a 34% YTD run, an in-line ~$0.43 FFO print with no guidance raise could disappoint a stock that's priced in good news.
Rate headwinds accelerate. The June refi and higher-for-longer rates pressure H2 earnings; macro/Fed commentary matters.
Janus complexity. Consolidation optics, minority-interest deductions, and undeployed-cash drag can muddy the headline — management will need to keep bridging investors to the "clean" run-rate.
Broader macro/policy noise. Healthcare policy (drug pricing / MFN), life-science funding volatility, and the general REIT rate backdrop remain wild cards.

Bottom Line

The core question for Q2 isn't the headline FFO number — a ~$0.42–$0.43 print is expected and shouldn't be read as a miss given Q1 was front-loaded. The report is really a checkpoint on three things: (1) is lab occupancy genuinely inflecting toward the +100 bps year-end goal; (2) is management executing the $700M+ recycling pipeline and deploying Janus cash into accretive senior housing deals; and (3) does the outlook support the stock's meaningful re-rating. Outpatient medical should again be rock-solid, senior housing (Janus) should again be the growth star, and the swing vote — as it has been for two years — is life science.

Note: A separate Janus Living (JAN) earnings call typically follows Healthpeak's and will carry the detailed senior housing metrics; investors should treat the two calls as a pair.

This preview is based on Healthpeak's Q1 2026 and Q2 2025 earnings materials, transcripts, and market data through Aug 3, 2026. Figures are as reported by the company; forward statements reflect management guidance, not outcomes. This is informational analysis, not investment advice.